USA: Results from the pivotal STORM-PE randomized controlled trial, presented as a Late-Breaking Clinical Trial at TCT 2025, ...
The first of its kind RCT in acute intermediate-high-risk PE used a surrogate endpoint, but more data are on the horizon.
Penumbra, Inc. (NYSE: PEN) announced the results of the landmark STORM-PE randomized controlled trial (RCT), which found that ...